2型糖尿病患者肾脏生物标志物与eGFR下降
在EXAMINE试验的5367例2型糖尿病合并近期急性冠脉综合征患者中,评估血清胱抑素C、尿KIM-1和尿NGAL与eGFR下降的关联。中位随访1.5年,98例(1.8%)发生eGFR下降。调整基线eGFR、蛋白尿和临床因素后,仅基线胱抑素C和6个月尿NGAL变化独立相关,但添加生物标志物未显著改善预测。
要点
- 基线胱抑素C独立关联eGFR下降(校正HR 1.66,95%CI 1.41-1.96)。
- 6个月尿NGAL变化独立关联eGFR下降(校正HR 1.07,95%CI 1.02-1.12)。
- 添加胱抑素C或肾小管损伤标志物未显著改善风险预测。
核心结论
- 在2型糖尿病合并近期急性冠脉综合征患者中,添加胱抑素C或肾小管损伤生物标志物未能在常见临床因素和常规实验室数据之外显著改善eGFR下降的预测。
研究设计与样本
- EXAMINE试验的事后分析,纳入5367例2型糖尿病合并近期急性冠脉综合征患者,检测基线及6个月时的血清胱抑素C、尿KIM-1和尿NGAL。
主要发现
- 中位随访1.5年,98例(1.8%)发生eGFR下降。
- 所有生物标志物单独均与eGFR下降风险升高相关(P<0.001)。
- 调整基线eGFR、蛋白尿和临床因素后,仅基线胱抑素C(校正HR 1.66,95%CI 1.41-1.96,P<0.001)和6个月尿NGAL变化(校正HR 1.07,95%CI 1.02-1.12,P=0.004)独立关联CKD进展。
- 包含9个标准风险因素的基线模型预测肾功能下降的C-statistic为0.93,添加基线胱抑素C后为0.94,但未能重新分类风险类别。
临床怎么用
- 在2型糖尿病合并近期急性冠脉综合征患者中,常规临床因素和实验室数据已能较好预测eGFR下降,添加胱抑素C或肾小管损伤标志物未显著改善风险分层。
局限性
- 研究人群为2型糖尿病合并近期急性冠脉综合征患者,结果可能不适用于其他人群。
- eGFR下降事件数较少(98例),可能限制统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Biomarkers may improve identification of individuals at risk of eGFR decline who may benefit from intervention or dialysis planning. However, available biomarkers remain incompletely validated for risk stratification and prediction modeling. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We examined serum cystatin C, urinary kidney injury molecule-1 (uKIM-1), and urinary neutrophil gelatinase-associated lipocalin (UNGAL) in 5367 individuals with type 2 diabetes mellitus and recent acute coronary syndromes enrolled in the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial. Baseline concentrations and 6-month changes in biomarkers were also evaluated. Cox proportional regression was used to assess associations with a 50% decrease in eGFR, stage 5 CKD (eGFR<15 ml/min per 1.73 m2), or dialysis. RESULTS: eGFR decline occurred in 98 patients (1.8%) over a median of 1.5 years. All biomarkers individually were associated with higher risk of eGFR decline (P<0.001). However, when adjusting for baseline eGFR, proteinuria, and clinical factors, only baseline cystatin C (adjusted hazard ratio per 1 SD change, 1.66; 95% confidence interval, 1.41 to 1.96; P<0.001) and 6-month change in urinary neutrophil gelatinase-associated lipocalin (adjusted hazard ratio per 1 SD change, 1.07; 95% confidence interval, 1.02 to 1.12; P=0.004) independently associated with CKD progression. A base model for predicting kidney function decline with nine standard risk factors had strong discriminative ability (C-statistic 0.93). The addition of baseline cystatin C improved discrimination (C-statistic 0.94), but it failed to reclassify risk categories of individuals with and without eGFR decline. CONCLUSIONS: The addition of cystatin C or biomarkers of tubular injury did not meaningfully improve the prediction of eGFR decline beyond common clinical factors and routine laboratory data in a large cohort of patients with type 2 diabetes and recent acute coronary syndrome. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2018_01_16_CJASNPodcast_18_3_G.mp3.
引用
- Garlo KG, White WB, Bakris GL, et al. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018. PMID: 29339356. doi:10.2215/CJN.05280517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。